Table 2.
(A and B) mouse (host) and(C and D) human (from xenograft tumor) immune-related protein antigen profiling
| (A) Protein expression level up-regulated | |||
|---|---|---|---|
| Antigen names | GLV-1h68/untreated ratio |
Classification | |
| Day 21 | Day 42 | ||
| MCP-5 (CCL12) | 25.59 | 39.05 | Proinflammatory cytokine |
| IL-18 | 14.1 | 33.98 | Proinflammatory cytokine |
| MCP-1 (CCL2) | 14.02 | 21.8 | Proinflammatory chemokine |
| MCP-3 (CCL7) | 10.59 | 12.23 | Proinflammatory chemokine |
| IP-10 (CXCL10) | 10.48 | 11.24 | Proinflammatory chemokine |
| Eotaxin (CCL11) | 7.44 | 5.56 | Proinflammatory chemokine |
| GCP-2 (CXCL6) | 5.49 | 3.69 | Proinflammatory cytokine |
| Gro-β (MIP-2) | 4.82 | 3.59 | Proinflammatory chemokine |
| IL-6 | 4.08 | 7.82 | Proinflammatory cytokine |
| C-reactive protein | 3.98 | 3.29 | Proinflammatory protein |
| M-CSF (KC/GROα) | 2.20 | 4.06 | Proinflammatory chemokine |
| IL-11 | 6.02 | 4.06 | Pleiotropic cytokine |
| Thrombopoietin | 2.22 | 2.07 | Lineage-specific cytokine |
| Apolipoprotein A1 | 6.87 | 6.77 | Anti-inflammatory protein |
| MPO (myeloperoxidase) | 5.62 | 2.65 | Peroxidase enzyme |
| Matrix metalloproteinase-9 | 10.7 | 6.38 | Enzyme |
| TIMP-1 | 14.26 | 13.8 | Protein inhibitor |
| (B) Protein expression level down-regulated | |||
| Antigen names | Untreated/GLV-1h68 ratio |
Classification | |
| Day 21 | Day 42 | ||
| MIP-1γ (CCL9) | 9.70 | 13.11 | Cytokine |
| RANTES (CCL5) | 4.41 | 7.45 | Proinflammatory chemokine |
| MIP-1β | 2.89 | 2.17 | β-Chemokine |
| (C) Protein expression level up-regulated | |||
| GLV-1h68/untreated | |||
| Ferritin | 5.1 | ||
| Plasminogen activator inhibitor-1 | 4.6 | ||
| Tissue factor | 3.4 | ||
| von Willebrand factor | 2.8 | ||
| MCP-1 (CCL2) | 2.7 | ||
| TIMP-1 | 2.6 | ||
| Brain-derived neurotrophic factor | 2.3 | ||
| PAPP-A | 2.3 | ||
| Basic fibroblast growth factor | 2.1 | ||
| IL-1α | 2.1 | ||
| (D) Protein expression level down-regulated | |||
| Untreated/GLV-1h68 | |||
| Epidermal growth factor | 10.7 | ||
| Insulin-like growth factor-I | 8.2 | ||
| Fatty acid binding protein | 5.7 | ||
| TNF-β | 3.9 | ||
| IL-12p40 | 3.2 | ||
| MIP-1β | 3.2 | ||
| IL-2 | 3.0 | ||
| Factor VII | 2.3 | ||
| IL-1ra | 2.2 | ||
| β2-Microglobulin | 2.1 | ||
| Creatine kinase-MB | 2.1 | ||
| RANTES | 2.1 | ||
| Prostatic acid phosphatase | 2.0 | ||
| Note: | |||
| Fold of enhancement | Fold of suppression | ||
| 2-3 | 2-3 | ||
| 3-5 | 3-5 | ||
| >5 | >5 | ||
NOTE: S.c. PANC-1 tumors in nude mice with or without GLV-1h68 treatment. Time points were taken 21 d after virus i.v. injection. Folds of enhancement or suppression of protein expression after virus injection are shown (n = 2).